Kennon Green & Company LLC Increases Stock Holdings in Kenvue Inc. (NYSE:KVUE)

Kennon Green & Company LLC boosted its holdings in Kenvue Inc. (NYSE:KVUE) by 100.4% during the fourth quarter, Holdings Channel reports. The institutional investor owned 35,438 shares of the company’s stock after buying an additional 17,753 shares during the period. Kennon Green & Company LLC’s holdings in Kenvue were worth $763,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. acquired a new position in shares of Kenvue during the third quarter worth about $2,944,816,000. FMR LLC lifted its position in Kenvue by 572.1% during the 3rd quarter. FMR LLC now owns 89,182,980 shares of the company’s stock worth $1,790,794,000 after acquiring an additional 75,913,107 shares in the last quarter. Wellington Management Group LLP boosted its holdings in Kenvue by 576.1% in the 3rd quarter. Wellington Management Group LLP now owns 71,686,830 shares of the company’s stock worth $1,439,472,000 after acquiring an additional 61,084,123 shares during the period. Massachusetts Financial Services Co. MA grew its position in Kenvue by 227.7% in the third quarter. Massachusetts Financial Services Co. MA now owns 61,091,189 shares of the company’s stock valued at $1,226,711,000 after acquiring an additional 42,449,470 shares in the last quarter. Finally, Morgan Stanley grew its holdings in Kenvue by 4,057.4% during the 3rd quarter. Morgan Stanley now owns 31,162,614 shares of the company’s stock valued at $625,745,000 after purchasing an additional 30,413,040 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Trading Up 0.4 %

Shares of NYSE KVUE traded up $0.08 during midday trading on Monday, hitting $18.94. The company’s stock had a trading volume of 9,085,689 shares, compared to its average volume of 16,595,035. The company has a current ratio of 1.12, a quick ratio of 0.78 and a debt-to-equity ratio of 0.69. Kenvue Inc. has a 1-year low of $17.82 and a 1-year high of $27.80. The firm’s fifty day moving average price is $19.84 and its 200-day moving average price is $20.14.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, February 8th. The company reported $0.31 EPS for the quarter, beating analysts’ consensus estimates of $0.28 by $0.03. The company had revenue of $3.67 billion during the quarter, compared to the consensus estimate of $3.78 billion. Kenvue had a return on equity of 15.62% and a net margin of 9.87%. The firm’s revenue was down 2.7% on a year-over-year basis. On average, equities research analysts forecast that Kenvue Inc. will post 1.15 earnings per share for the current year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 22nd. Investors of record on Wednesday, May 8th will be given a dividend of $0.20 per share. The ex-dividend date is Tuesday, May 7th. This represents a $0.80 dividend on an annualized basis and a yield of 4.22%.

Analyst Ratings Changes

Several research analysts recently commented on KVUE shares. Sanford C. Bernstein initiated coverage on Kenvue in a research note on Thursday, April 11th. They issued an “underperform” rating and a $18.00 price target on the stock. Royal Bank of Canada cut their target price on Kenvue from $25.00 to $24.00 and set an “outperform” rating on the stock in a research report on Friday, February 9th. JPMorgan Chase & Co. decreased their price target on shares of Kenvue from $25.00 to $24.00 and set an “overweight” rating for the company in a research report on Friday, February 9th. The Goldman Sachs Group started coverage on shares of Kenvue in a research note on Friday, March 1st. They issued a “neutral” rating and a $20.00 price target for the company. Finally, William Blair assumed coverage on shares of Kenvue in a research note on Wednesday, April 3rd. They set a “market perform” rating on the stock. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $24.85.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.